Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Scientific and Technical Research Council of Turkey Country of Publication: Turkey NLM ID: 9441758 Publication Model: eCollection Cited Medium: Internet ISSN: 1303-6165 (Electronic) Linking ISSN: 13000144 NLM ISO Abbreviation: Turk J Med Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Ankara : Scientific and Technical Research Council of Turkey, [1994-
    • Subject Terms:
      Meningioma*/pathology ; Meningioma*/immunology ; Meningioma*/metabolism ; B7-H1 Antigen*/analysis ; B7-H1 Antigen*/metabolism ; Meningeal Neoplasms*/pathology ; Meningeal Neoplasms*/metabolism ; Meningeal Neoplasms*/immunology ; Immunohistochemistry* ; Programmed Cell Death 1 Receptor*/metabolism ; Programmed Cell Death 1 Receptor*/analysis; Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/analysis ; Aged, 80 and over ; Immunotherapy ; Young Adult
    • Abstract:
      Background/aim: Meningiomas are the most common primary brain tumors of the central nervous system. Immunotherapy is a promising treatment method applied in many types of cancer. There is no standard and effective medical treatment to reduce recurrence and mortality in cases of incomplete resection of meningiomas and in high-grade cases. In order to investigate medical treatments in addition to surgery and radiotherapy, in this study, the status of immune checkpoint molecules (PD-L1/PD-1), which are the target of immunotherapy, in meningiomas was investigated.
      Materials and Methods: Four hundred two cases of meningioma diagnosed between 2007 and 2020 at our institution were used. New blocks were prepared from the appropriate blocks of the cases using the tissue microarray method. Sections obtained from these blocks were immunohistochemically stained with PD-1 and PD-L1 antibodies. Obtained data were interpreted with statistical analysis.
      Results: Expression of PD-L1 was observed in 28.4% of meningiomas. Staining rates are higher in high-grade tumors. The staining rate of PD-L1 in the tumor increased significantly with pattern loss. PD-L1 expression in immune cells is 19.9%. Immune cell expression and the number of expressing immune cells correlate with spontaneous necrosis. Immune cell expression and the number of expressing immune cells are increased in high-grade meningiomas. PD-1 expression in immune cells is 9.0%, and this correlates with brain invasion.
      Conclusions: With these data, it was observed that the expression of immune checkpoint molecules PD-L1 and PD-1 increased especially in high-grade meningiomas. It may be the subject of research that these molecules may be targets of immunotherapy in the treatment of meningiomas.
      Competing Interests: Conflict of interest: The authors declare that there are no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
      (© TÜBİTAK.)
    • References:
      Front Oncol. 2020 Jan 08;9:1472. (PMID: 31970090)
      J Clin Neurosci. 2018 Nov;57:149-151. (PMID: 30153998)
      Am J Clin Oncol. 2016 Feb;39(1):98-106. (PMID: 26558876)
      J Neurooncol. 2018 Sep;139(2):469-478. (PMID: 29846894)
      Cancer Immunol Immunother. 2019 Jun;68(6):999-1009. (PMID: 31030234)
      BMC Cancer. 2017 Feb 13;17(1):127. (PMID: 28193203)
      JCO Precis Oncol. 2018;2018:. (PMID: 30801050)
      Clin Neurol Neurosurg. 2016 Feb;141:117-21. (PMID: 26780494)
      Am J Pathol. 2012 Nov;181(5):1749-61. (PMID: 22982440)
      Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62. (PMID: 26511214)
      Cancer Immunol Immunother. 2016 May;65(5):537-49. (PMID: 26961085)
      Neurosurg Focus. 2018 Apr;44(4):E3. (PMID: 29606052)
      J Neurooncol. 2016 Dec;130(3):543-552. (PMID: 27624915)
      J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39. (PMID: 13406590)
      JCI Insight. 2019 Oct 17;4(20):. (PMID: 31536478)
      Oncotarget. 2015 Mar 10;6(7):4704-16. (PMID: 25609200)
      Cancer. 1999 May 1;85(9):2046-56. (PMID: 10223247)
      J Neurooncol. 2019 Aug;144(1):11-20. (PMID: 31177425)
      Nat Genet. 2013 Mar;45(3):285-9. (PMID: 23334667)
      Genes Chromosomes Cancer. 1994 Jun;10(2):122-30. (PMID: 7520265)
      Immunotherapy. 2016 Jun;8(6):721-31. (PMID: 27197540)
      Sci Rep. 2020 Aug 24;10(1):14115. (PMID: 32839486)
      J Clin Neurosci. 2017 Mar;37:51-53. (PMID: 28089420)
      Cancer Immunol Immunother. 2022 Sep;71(9):2067-2075. (PMID: 35092481)
      Lancet. 2016 Apr 30;387(10030):1837-46. (PMID: 26970723)
      Nat Rev Immunol. 2015 Aug;15(8):486-99. (PMID: 26205583)
      J Neurooncol. 2021 Feb;151(3):443-449. (PMID: 33611710)
      Eur Urol. 2015 Aug;68(2):267-79. (PMID: 25824720)
      PLoS One. 2013 Oct 01;8(10):e74798. (PMID: 24098347)
    • Contributed Indexing:
      Keywords: PD-1; PD-L1; immune checkpoint; immunotherapy; meningioma
    • Accession Number:
      0 (B7-H1 Antigen)
      0 (CD274 protein, human)
      0 (Programmed Cell Death 1 Receptor)
      0 (PDCD1 protein, human)
      0 (Biomarkers, Tumor)
    • Publication Date:
      Date Created: 20240919 Date Completed: 20240919 Latest Revision: 20240920
    • Publication Date:
      20240920
    • Accession Number:
      PMC11407334
    • Accession Number:
      10.55730/1300-0144.5843
    • Accession Number:
      39295608